35 results about "Increased heart rate" patented technology

Disclosed herein are methods, systems, and apparatus for treating a medical condition of a patient, involving detecting a physiological cycle or cycles of the patient and applying an electrical signal to a portion of the patient's vagus nerve through an electrode at a selected point in the physiological cycle(s). The physiological cycle can be the cardiac and/or respiratory cycle. The selected point can be a point in the cardiac cycle correlated with increased afferent conduction on the vagus nerve, such as a point from about 10 msec to about 800 msec after an R-wave of the patient's ECG, optionally during inspiration by the patient. The selected point can be a point in the cardiac cycle when said applying increases heart rate variability, such as a point from about 10 msec to about 800 msec after an R-wave of the patient's ECG, optionally during expiration by the patient.

A method of assessing cardiac ischemia in a subject to provide a measure of cardiovascular health in that subject is described. In general, the method comprises the steps of: (a) collecting a first RR-interval data set from the subject during a stage of gradually increasing heart rate; (b) collecting a second RR-interval data set from the subject during a stage of gradually decreasing heart rate (e.g., after an abrupt stop in exercise; during a stage of gradually decreasing exercise load; etc.); (c) separating fluctuations from a slow trend in the first RR-interval data set; (d) separating fluctuations from a slow trend in the second RR-interval data set; (e) comparing the fluctuations of the first RR-interval data set to the fluctuations of the second RR-interval data set to determine a difference between the fluctuation data sets; and (f) generating from the comparison of step (e) a measure of cardiac ischemia during stimulation in the subject, wherein a greater difference between the first and second data sets indicates greater cardiac ischemia and lesser cardiac or cardiovascular health in the subject.

Disclosed is a system for the detection of cardiac events that includes an implanted device called a cardiosaver, a physician's programmer and an external alarm system. The system is designed to provide early detection of cardiac events such as acute myocardial infarction or exercise induced myocardial ischemia caused by an increased heart rate or exertion. The system can also alert the patient with a less urgent alarm if a heart arrhythmia is detected. Using different algorithms, the cardiosaver can detect a change in the patient's electrogram that is indicative of a cardiac event within five minutes after it occurs and then automatically warn the patient that the event is occurring. To provide this warning, the system includes an internal alarm sub-system (internal alarm means) within the cardiosaver and/or an external alarm system (external alarm means) which are activated after the ST segment of the electrogram exceeds a preset threshold.

Disclosed is a system for the detection of cardiac events (a guardian system) that includes an implanted device called a cardiosaver, a physician's programmer and an external alarm system. The system is designed to provide early detection of cardiac events such as acute myocardial infarction or exercise induced myocardial ischemia caused by an increased heart rate or exertion. The system can also alert the patient with a less urgent alarm if a heart arrhythmia is detected. Using one or more detection algorithms, the cardiosaver can detect a change in the patient's electrogram that is indicative of a cardiac event within five minutes after it occurs and then automatically warn the patient that the event is occurring. To provide this warning, the guardian system includes an internal alarm sub-system (internal alarm means) within the cardiosaver and/or an external alarm system (external alarm means). If the guardian system is put into a pacemaker, the algorithm can utilize a different analysis of the electrogram depending on whether or not the pacemaker is actually pacing the heart.

The mdx mouse is a model of Duchenne muscular dystrophy. The present invention describes that mdx mice exhibited clinically relevant cardiac phenotypes. A non-invasive method of recording electrocardiograms (ECGs) was used to a study mdx mice (n=15) and control mice (n=15). The mdx mice had significant tachycardia, consistent with observations in patients with muscular dystrophy. Heart-rate was nearly 15% faster in mdx mice than control mice (P<0.01). ECGs revealed significant shortening of the rate-corrected QT interval duration (QTc) in mdx mice compared to control mice (P<0.05). PR interval duration were shorter at baseline in mdx compared to control mice (P<0.05). The muscarinic antagonist atropine significantly increased heart-rate and decreased PR interval duration in C57 mice. Paradoxically, atropine significantly decreased heart-rate and increased PR interval duration in all mdx mice. Pharmacological autonomic blockade and baroreflex sensitivity testing demonstrated an imbalance in autonomic nervous system modulation of heart-rate, with decreased parasympathetic activity and increased sympathetic activity in mdx mice. These electrocardiographic findings in dystrophin-deficient mice provide new bases for diagnosing, understanding, and treating patients with Duchenne muscular dystrophy.

The invention aims to solve the technical problems of the existing products and provides a method capable of increasing the heart rate detection accuracy, and the method can realize accurate detection to heart rate data by wearable equipment. Meanwhile, the invention provides a system capable of accurately detecting the heart rate accuracy. The two inventions provide a further guarantee for the life safety of old people.

Disclosed is a system for the detection of cardiac events that includes an implanted device called a cardiosaver, a physician's programmer and an external alarm system. The system is designed to provide early detection of cardiac events such as acute myocardial infarction or exercise induced myocardial ischemia caused by an increased heart rate or exertion. The system can also alert the patient with a less urgent alarm if a heart arrhythmia is detected. Using different algorithms, the cardiosaver can detect a change in the patient's electrogram that is indicative of a cardiac event within five minutes after it occurs and then automatically warn the patient that the event is occurring. To provide this warning, the system includes an internal alarm sub-system (internal alarm means) within the cardiosaver and/or an external alarm system (external alarm means) which are activated after the ST segment of the electrogram exceeds a preset threshold.

The invention discloses application of atractylodin in the preparation of drugs for treating and preventing heart failure, and belongs to the field of medicine. Atractylodin can significantly increase maximum rising speed of left ventricular developed pressure and left ventricular pressure of rat isolated heart, is dependent on concentration, causes no significant effect on heart rate, and is free of adverse effect causing arrhythmia. It is indicated that atractylodin has positive inotropic action and is not dependent on neurohumor. Atractylodin can significantly increase a normal rat's end-systolic volume, end-systolic pressure, stroke volume, ejection fraction, cardiac output, left ventricular pressure maximum rising speed, stroke work, and slope of end-systolic pressure-volume relational curve. It is indicated that atractylodin has positive inotropic action without increasing heart rate.

A method of assessing cardiac ischemia in a subject to provide a measure of cardiac or cardiovascular health in that subject is described herein. The method comprises the steps of: (a) collecting a first RR-interval data set from said subject during a stage of gradually increasing heart rate up to a predetermined heart rate of at least 130 beats per minute; (b) collecting a second RR-interval data set from said subject during a stage of gradually decreasing heart rate; (c) comparing said first RR-interval data set to said second RR-interval data set to determine the difference between said data sets; and (d) generating from said comparison of step (c) a measure of cardiac ischemia during stimulation in said subject, wherein a greater difference between said first and second data sets indicates greater cardiac ischemia and lesser cardiac or cardiovascular health in said subject.

The invention belongs to the technical field of biology, and particularly relates to a novel PEG-modified recombinant human granulocyte colony-stimulating factor preparation. The PEG-modified recombinant human granulocyte colony-stimulating factor preparation at least comprises pegylated recombinant human granulocyte colony-stimulating factors, auxiliary materials and water for injection, whereinthe concentration of the PEG-modified recombinant human granulocyte colony-stimulating factors is 5-15 mg/mL, and the pH value of the PEG-modified recombinant human granulocyte colony-stimulating factor preparation is 4-4.4. According to the novel pegylated recombinant human granulocyte colony-stimulating factor preparation provided by the invention, the use of polysorbate as a stabilizer is avoided, and the human body is unlikely to suffer from side effects of blood pressure reduction, heart rate acceleration, hemolysis and the like. Arginine is used for replacing polysorbate, so that a stabilizing effect on a protein structure is achieved, the formation of protein aggregates is remarkably reduced, and the stability effect on the pegylated recombinant human granulocyte colony-stimulatingfactors is remarkably improved.

The invention discloses a therapeutic apparatus, and belongs to the technical field of medical equipment. A therapeutic apparatus is characterized in that a gas supply pipeline of the therapeutic apparatus is provided with a gas supply unit, and a pressure adjusting unit for processing output gas of the gas supply unit is arranged between the gas supply unit and a user inhalation device in the therapeutic apparatus. The pressure regulating unit comprises a gas storage part for receiving gas at the output end of the gas supply unit and realizing temporary storage; the air pump is used as a transmission device to transmit air, so that the pressure and the flow of the output air are average and stable, the breathing difficulty of an inhaler caused by unstable output air pressure is avoided, the heart rate of the inhaler is prevented from being increased, the cerebral anoxia condition of the inhaler is avoided, and the breathing quality of the inhaler is improved. Further, symptoms such as dizziness, headache, nausea, vomiting and weakness of an inhaler are avoided, and conditions such as pulmonary edema and coma are avoided.

The invention relates to the technical field of medical appliances and particularly relates to an auxiliary device for interventional therapy of a cardiovascular department. The auxiliary device comprises a bleeding arresting device, a monitoring device and a base, wherein the monitoring device is arranged on the base and is fixedly connected with the bleeding arresting device; the monitoring device comprises a monitoring frame, an electrocardiogram monitor and a dynamic blood pressure monitor are arranged at the top of the monitoring frame, the interior of the monitoring frame is partitionedinto a medicine placement groove, an appliance groove and a refuse chute by a plurality of transverse plates, and the medicine placement groove is partitioned into a normal-temperature area and a low-temperature area by a longitudinal plate; and the bleeding arresting device comprises an inverse-L-shaped rod, an electric telescopic rod and a pressing assembly, the inverse-L-shaped rod is fixedly connected with a fixed end of the electric telescopic rod, a telescopic end of the electric telescopic rod is fixedly connected with the pressing assembly, the inverse-L-shaped rod is further connectedwith a universal rod, and the universal rod is fixedly connected with a monitoring camera. According to the auxiliary device for the interventional therapy of the cardiovascular department, remote observation by medical personnel is achieved, an alert can be issued in time after increased heart rate and decreased heart rate phenomena occur, and the medical personnel can conveniently handle in time.

The invention discloses a pharmaceutical composition, which is composed of ginkgo flavonoids and ginkgolide according to a certain ratio, and also discloses a preparation prepared from the composition, a preparation method, an identification method and an effective ingredient content determination method. The composition and its preparation can be used for the treatment of ischemic stroke and cerebral infarction, and have the effects of increasing heart rate, increasing coronary artery flow, improving microcirculation and increasing local blood flow.

A method of determining the susceptibility to ventricular arrhythmias in a subject, comprises the steps of: (a) collecting (e.g., by surface EKG or intracardiac EKG) at least one QT and DI interval data set from the subject during a stage of gradually increasing heart rate or a stage of gradually decreasing heart rate; (b) determining (e.g., by applying low- and high pass filtering) low-frequency QT-DI interval trends and high-frequency QT-DI fluctuation signals in said at least one QT and DI interval data set; (c) finding a plurality of correlated and anti-correlated portions between said high-frequency QT-DI fluctuation signals; (d) determining corresponding regression lines for said correlated and anti-correlated portions; (e) finding a plurality of (or in some embodiments all) steady state QT-DI points designated by intersections between said low frequency QT-DI trends and said corresponding regression lines; (f) fitting action potential durations computed from a rate dependent reaction-diffusion model to corresponding ones of said steady state QT-DI points to give (i) a model excitation threshold and (ii) a minimal level of refractoriness at a plurality of (or in some embodiments all of) said steady state QT-DI points; (g) at the steady state QT-DI point corresponding to the highest heart rate in said QT and DI interval data set, determining the difference between said minimal level of refractoriness and a model critical excitation threshold for a stable solitary pulse corresponding to the rate dependent reaction diffusion model of step (f) to give a reserve of refractoriness (RoR); (h) fitting action potential durations computed from a rate dependent reaction-diffusion model to said correlated and anti-correlated portions to give a rate of adaptation of each model excitation threshold to a corresponding steady state value at a plurality of (or in some embodiments all of) said steady state QT-DI points; (i) at the steady state QT-DI point corresponding to the highest heart rate in said QT and DI interval data set, determining the inverse of said rate of adaptation to give a reserve of memory (RoM); (j) combining said reserve of refractoriness (RoR) and said reserve of memory (RoM) to produce a metric of stability-of-propagation reserve (SoPR) in said subject, a higher value of SoPR indicating lower susceptibility to ventricular arrhythmias in said subject. Systems and apparatus for carrying out the method are also described.

The present invention addresses the problem of providing an agent for decreasing heart rate having fewer side effects, or a novel agent for suppressing an increase in heart rate during exercise. The heart rate can be decreased, in particular, palpitation, shortness of breath or fatigue associated with an increased heart rate can be prevented or ameliorated, and the increase in heart rate during exercise can be suppressed by ingesting a preparation containing orotic acid or a salt thereof as an active ingredient.

The invention relates to a traditional Chinese medicine for treating bradyarrhythmia, which can effectively solve the problems of poor and slow curative effect and long therapy period in therapy of the bradyarrhythmia in traditional Chinese medicine. The traditional Chinese medicine includes 8-10 g of red ginseng, 5-7 g of processed radix aconiti lateralis, 10-14 g of herba ephedra, 10-14 g of cassia twigs, 10-14 g of rhizoma chuanxiong, 10-14 g of flos carthami, 2-4 g of asarum, 16-20 g of radix ophiopogonis, 27-33 g of herba epimedii, 27-33 g of rhizoma curculiginis and 13-17 g of cornu cervi degelatinatum. The traditional Chinese medicine has reasonable combination and achieves synergistic effect, has both warming and clearing functions and can regulate both Qi and blood. Due to combination of the raw materials, the traditional Chinese medicine has effects of boosting Qi and warming Yang, activating blood and resolving stasis, quieting spirit and relieving palpitation, can significantly relieving the clinical symptoms of the bradyarrhythmia, increases heart rate of a patient, improves coronary microcirculation, improves blood and oxygen supplement in myocardium and improves metabolic capability of myocardial cells, thereby improving heart excitation and conducting functions and fundamentally treating the bradyarrhythmia. The traditional Chinese medicine is safe and reliableto use.